Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: A multicenter phase II DeCOG trial

Annals of Oncology

Volumn 22, Issue 7, 2011, Pages 1667-1674

  Egberts, F ^a   Gutzmer, R ^b   Ugurel, S ^c,d   Becker, J C ^c,d   Trefzer, U ^e   Degen, A ^b   Schenck, F ^b   Frey, L ^c   Wilhelm, T ^e   Hassel, J C ^f   Schadendorf, D ^g   Livingstone, E ^a,g   Mauch, C ^h   Garbe, C ⁱ   Berking, C ^j   Rass, K ^k   Mohr, P ^l   Kaehler, K C ^a   Weichenthal, M ^a   Hauschild, A ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF GRAZ   (Austria)

^e HUMBOLDT UNIVERSITY   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g UNIVERSITY OF DUISBURG ESSEN   (Germany)

^h UNIVERSITY OF COLOGNE   (Germany)

ⁱ UNIVERSITY OF TÜBINGEN   (Germany)

^j LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^k SAARLAND UNIVERSITY   (Germany)

^l Dermatology Center   (Germany)

more..

Author keywords

Metastatic melanoma; Pegylated IFN; Sorafenib

Indexed keywords

LACTATE DEHYDROGENASE; PEGINTERFERON ALPHA2B; SORAFENIB;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ARTICLE; BLEEDING; BLOOD DISEASE; BLOOD TOXICITY; BONE MARROW DISEASE; BRAIN HEMORRHAGE; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER STAGING; CANCER SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAR DISEASE; ENDOCRINE DISEASE; EYE DISEASE; FATIGUE; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEART DISEASE; HEPATOBILIARY DISEASE; HUMAN; IMMUNOPATHOLOGY; INFECTION; KIDNEY DISEASE; LEUKOPENIA; LIMB PERFUSION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MELANOMA; METABOLIC DISORDER; METASTASIS POTENTIAL; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PAIN; PANCREAS DISEASE; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESPIRATORY TRACT DISEASE; SKIN DISEASE; SOFT TISSUE DISEASE; SURVIVAL TIME; THROMBOCYTOPENIA; TUMOR LOCALIZATION; UPPER RESPIRATORY TRACT INFECTION; UROGENITAL TRACT DISEASE; VISCERAL METASTASIS;

EID: 79959736969     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq648     Document Type: Article

References (21)

1. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
2. Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003; 4: 748-759.
3. Grob JJ, Dreno B, de la Salmoniere P et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998; 351: 1905-1910.
4. Kirkwood JM, Strawderman MH, Ernstoff MS et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7-17.
5. Dummer R, Garbe C, Thompson JA et al. Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. J Clin Oncol 2006; 24: 1188-1194.
6. Zeuzem S, Feinman SV, Rasenack J et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-1672.
7. Heathcote EJ, Shiffman ML, Cooksley WG et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673-1680.
8. Eggermont AM, Suciu S, Santinami M et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372: 117-126.
9. Omholt K, Platz A, Kanter L et al. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 2003; 9: 6483-6488.
10. McDermott DF, Sosman JA, Gonzalez R et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 2008; 26: 2178-2185.
11. Amaravadi RK, Schuchter LM, McDermott DF et al. Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases. Clin Cancer Res 2009; 15: 7711-7718.
12. Escudier B, Lassau N, Angevin E et al. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 2007; 13: 1801-1809.
13. Gollob JA, Rathmell WK, Richmond TM et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 2007; 25: 3288-3295.
14. Ryan CW, Goldman BH, Lara PN Jr et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 2007; 25: 3296-3301.
15. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 2006; 42: 1031-1039.
16. Eisen T, Ahmad T, Flaherty KT et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 2006; 95: 581-586.
17. Dummer R, Garbe C, Thompson JA et al. Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. J Clin Oncol 2006; 24: 1188-1194.
18. Korn EL, Liu PY, Lee SJ et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008; 26: 527-534.
19. Flaherty KT. Chemotherapy and targeted therapy combinations in advanced melanoma. Clin Cancer Res 2006; 12: 2366s-2370s.
20. Hauschild A, Agarwala SS, Trefzer U et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009; 27: 2823-2830.
21. Topcu-Yilmaz P, Kiratli H, Saglam A et al. Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma. Melanoma Res 2010; 20(2): 126-132.